Annual total expenses:
$463.85M-$27.83M(-5.66%)Summary
- As of today (June 22, 2025), HALO annual total expenses is $463.85 million, with the most recent change of -$27.83 million (-5.66%) on December 31, 2024.
- During the last 3 years, HALO annual total expenses has risen by +$296.44 million (+177.08%).
- HALO annual total expenses is now -5.66% below its all-time high of $491.68 million, reached on December 31, 2023.
Performance
HALO Total expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Quarterly total expenses:
$123.33M+$819.00K(+0.67%)Summary
- As of today (June 22, 2025), HALO quarterly total expenses is $123.33 million, with the most recent change of +$819.00 thousand (+0.67%) on March 31, 2025.
- Over the past year, HALO quarterly total expenses has increased by +$22.99 million (+22.91%).
- HALO quarterly total expenses is now -4.40% below its all-time high of $129.00 million, reached on December 31, 2023.
Performance
HALO Quarterly total expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Total expenses Formula
Total Expenses = Cost of Goods Sold + Operating Expenses + Non Operating Expenses
HALO Total expenses Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -5.7% | +22.9% |
| 3 y3 years | +177.1% | +196.4% |
| 5 y5 years | +76.0% | +331.6% |
HALO Total expenses Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -5.7% | +177.1% | -4.4% | +196.4% |
| 5 y | 5-year | -5.7% | +276.1% | -4.4% | +393.0% |
| alltime | all time | -5.7% | >+9999.0% | -4.4% | >+9999.0% |
HALO Total expenses History
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2025 | - | $123.33M(+0.7%) |
| Dec 2024 | $463.85M(-5.7%) | $122.51M(-3.5%) |
| Sep 2024 | - | $126.89M(+11.2%) |
| Jun 2024 | - | $114.12M(+13.7%) |
| Mar 2024 | - | $100.34M(-22.2%) |
| Dec 2023 | $491.68M(+25.2%) | $129.00M(+1.0%) |
| Sep 2023 | - | $127.75M(+0.9%) |
| Jun 2023 | - | $126.58M(+16.8%) |
| Mar 2023 | - | $108.34M(+1.3%) |
| Dec 2022 | $392.58M(+134.5%) | $106.99M(-14.9%) |
| Sep 2022 | - | $125.68M(+6.2%) |
| Jun 2022 | - | $118.31M(+184.3%) |
| Mar 2022 | - | $41.61M(-8.5%) |
| Dec 2021 | $167.41M(+35.7%) | $45.47M(+13.0%) |
| Sep 2021 | - | $40.24M(-7.3%) |
| Jun 2021 | - | $43.41M(+13.4%) |
| Mar 2021 | - | $38.29M(-13.1%) |
| Dec 2020 | $123.34M(-53.2%) | $44.08M(+76.2%) |
| Sep 2020 | - | $25.02M(-2.5%) |
| Jun 2020 | - | $25.67M(-10.2%) |
| Mar 2020 | - | $28.58M(-66.7%) |
| Dec 2019 | $263.60M(+19.2%) | $85.73M(+21.1%) |
| Sep 2019 | - | $70.77M(+33.2%) |
| Jun 2019 | - | $53.13M(-1.6%) |
| Mar 2019 | - | $53.98M(-10.5%) |
| Dec 2018 | $221.19M(-6.1%) | $60.30M(+18.2%) |
| Sep 2018 | - | $51.03M(-7.7%) |
| Jun 2018 | - | $55.27M(+1.3%) |
| Mar 2018 | - | $54.58M(-14.2%) |
| Dec 2017 | $235.61M(+2.5%) | $63.63M(+14.3%) |
| Sep 2017 | - | $55.65M(-6.0%) |
| Jun 2017 | - | $59.23M(+3.7%) |
| Mar 2017 | - | $57.09M(-7.3%) |
| Dec 2016 | $229.90M(+41.5%) | $61.58M(+12.8%) |
| Sep 2016 | - | $54.60M(-0.8%) |
| Jun 2016 | - | $55.06M(-6.2%) |
| Mar 2016 | - | $58.67M(+25.5%) |
| Dec 2015 | $162.51M(+17.4%) | $46.76M(+6.2%) |
| Sep 2015 | - | $44.02M(+12.4%) |
| Jun 2015 | - | $39.15M(+20.2%) |
| Mar 2015 | - | $32.58M(-4.8%) |
| Dec 2014 | $138.37M(+2.3%) | $34.23M(+1.8%) |
| Sep 2014 | - | $33.63M(+0.9%) |
| Jun 2014 | - | $33.33M(-10.4%) |
| Mar 2014 | - | $37.19M(+9.9%) |
| Dec 2013 | $135.23M | $33.82M(-2.0%) |
| Sep 2013 | - | $34.51M(-5.7%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2013 | - | $36.58M(+20.6%) |
| Mar 2013 | - | $30.33M(+15.8%) |
| Dec 2012 | $95.95M(+26.4%) | $26.20M(+3.3%) |
| Sep 2012 | - | $25.36M(+16.3%) |
| Jun 2012 | - | $21.81M(-3.4%) |
| Mar 2012 | - | $22.58M(+8.4%) |
| Dec 2011 | $75.93M(+11.8%) | $20.84M(+17.1%) |
| Sep 2011 | - | $17.79M(-11.5%) |
| Jun 2011 | - | $20.09M(+16.8%) |
| Mar 2011 | - | $17.20M(-19.8%) |
| Dec 2010 | $67.88M(-5.9%) | $21.46M(+35.5%) |
| Sep 2010 | - | $15.83M(+3.0%) |
| Jun 2010 | - | $15.37M(+0.9%) |
| Mar 2010 | - | $15.23M(-20.3%) |
| Dec 2009 | $72.13M(+21.8%) | $19.12M(+12.7%) |
| Sep 2009 | - | $16.97M(-8.3%) |
| Jun 2009 | - | $18.51M(+5.6%) |
| Mar 2009 | - | $17.53M(-12.7%) |
| Dec 2008 | $59.20M(+85.3%) | $20.09M(+47.0%) |
| Sep 2008 | - | $13.66M(+6.7%) |
| Jun 2008 | - | $12.81M(+1.3%) |
| Mar 2008 | - | $12.64M(+12.2%) |
| Dec 2007 | $31.95M(+92.9%) | $11.27M(+21.8%) |
| Sep 2007 | - | $9.25M(+41.4%) |
| Jun 2007 | - | $6.54M(+33.8%) |
| Mar 2007 | - | $4.89M(-4.0%) |
| Dec 2006 | $16.56M(+21.0%) | $5.10M(+21.6%) |
| Sep 2006 | - | $4.19M(+18.5%) |
| Jun 2006 | - | $3.53M(-5.7%) |
| Mar 2006 | - | $3.75M(+3.1%) |
| Dec 2005 | $13.69M(+50.6%) | $3.63M(-4.1%) |
| Sep 2005 | - | $3.79M(+26.7%) |
| Jun 2005 | - | $2.99M(-8.5%) |
| Mar 2005 | - | $3.27M(+29.4%) |
| Dec 2004 | $9.09M(>+9900.0%) | $2.53M(-22.5%) |
| Sep 2004 | - | $3.26M(+56.2%) |
| Jun 2004 | - | $2.09M(+73.0%) |
| Mar 2004 | - | $1.21M(-217.0%) |
| Dec 2003 | $0.00(0.0%) | -$1.03M(-352.9%) |
| Sep 2003 | - | $408.20K(+9.5%) |
| Jun 2003 | - | $372.90K(+48.3%) |
| Mar 2003 | - | $251.40K(-449.2%) |
| Dec 2002 | $0.00(-100.0%) | -$72.00K(-344.9%) |
| Sep 2002 | - | $29.40K(+12.6%) |
| Jun 2002 | - | $26.10K(+58.2%) |
| Mar 2002 | - | $16.50K |
| Dec 2001 | $64.40K | - |
FAQ
- What is Halozyme Therapeutics annual total expenses?
- What is the all time high annual total expenses for Halozyme Therapeutics?
- What is Halozyme Therapeutics annual total expenses year-on-year change?
- What is Halozyme Therapeutics quarterly total expenses?
- What is the all time high quarterly total expenses for Halozyme Therapeutics?
- What is Halozyme Therapeutics quarterly total expenses year-on-year change?
What is Halozyme Therapeutics annual total expenses?
The current annual total expenses of HALO is $463.85M
What is the all time high annual total expenses for Halozyme Therapeutics?
Halozyme Therapeutics all-time high annual total expenses is $491.68M
What is Halozyme Therapeutics annual total expenses year-on-year change?
Over the past year, HALO annual total expenses has changed by -$27.83M (-5.66%)
What is Halozyme Therapeutics quarterly total expenses?
The current quarterly total expenses of HALO is $123.33M
What is the all time high quarterly total expenses for Halozyme Therapeutics?
Halozyme Therapeutics all-time high quarterly total expenses is $129.00M
What is Halozyme Therapeutics quarterly total expenses year-on-year change?
Over the past year, HALO quarterly total expenses has changed by +$22.99M (+22.91%)